

References

1. Al-Omary MS, Davies AJ, Evans T, et al. Mortality and readmission following hospitalisation for heart failure in Australia: A systematic review and meta-analysis. *Heart Lung Circ.* 2018;27:917–927.
2. Atherton JJ, Sindone A, De Pasquale CG, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the prevention, detection, and management of heart failure in Australia 2018. *Heart Lung Circ.* 2018;27(10):1123–1208.
3. Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts. 2024. Available at: <https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/all-heart-stroke-and-vascular-disease/heart-failure-and-cardiomyopathy>
4. Australian Institute of Health and Welfare. Disparities in potentially preventable hospitalisations across Australia, 2012–13 to 2017–18. Available at: <https://www.aihw.gov.au/reports/primary-health-care/disparities-in-potentially-preventable-hospitalisa/summary>
5. Bozkurt B, Savarese G, Adamsson Eryd S, et al. Mortality, outcomes, costs and use of medicines following a first heart failure hospitalisation (EVOLUTION HF). *JACC Heart Fail.* 2023;11(10):1320–1332.
6. Chen L, Booley S, Keates AK, Stewart S. Snapshot of heart failure in Australia. Mary MacKillop Institute for Health Research, Australian Catholic University; 2017. Available at: <https://www.acu.edu.au/about-acu/news/2017/june/snapshot-of-heart-failure-in-Australia>
7. Coons JC, Kliner J, Mathier MA, et al. Medication optimisation clinic decreases hospitalisations and mortality for patients with HFrEF. *Am Heart J Plus.* 2024;47:100470.
8. Driscoll A, Dinh D, Wong J, et al. Impact of individual patient profiles on adherence to guideline-directed medical therapy in HFrEF (VCOR-HF). *Heart Lung Circ.* 2020;29(12):1782–1789.
9. Driscoll A, Srivastava P, Toia D, et al. A nurse-led up-titration clinic improves beta-blocker optimisation in chronic heart failure: A randomised controlled trial. *BMC Res Notes.* 2014;7:668.
10. Ezekowitz JA, van Walraven C, McAlister FA, et al. Impact of specialist follow-up in outpatients with congestive heart failure. *CMAJ.* 2005;172(2):189–194.
11. Evans M, Morgan AR, Whyte MB, et al. New therapeutic horizons in chronic kidney disease: The role of SGLT2 inhibitors in clinical practice. *Drugs.* 2021;81:1243–1255.
12. Fonarow GC, Greene SJ. Rapid and intensive guideline-directed medical therapy for heart failure across the ejection fraction spectrum. *J Am Coll Cardiol.* 2023;81(22):2145–2148.
13. HealthPathways. Heart failure. 2023. Available at: <https://westvicphn.com.au/health-professionals/general-practice-support/healthpathways/>
14. Indraratna U, Biswas J, McVeigh A, et al. A randomised controlled trial of TeleClinical Care – a smartphone-app-based model of care for heart failure and acute coronary syndromes. *Eur Heart J.* 2021;42(Supplement 1):ehab724.3083.
15. Maddox TM, Januzzi JL, Allen LA, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimisation of heart failure treatment. *J Am Coll Cardiol.* 2021;77(6):772–810.
16. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2021;42(36):3599–3726.

References (cont.)

17. McDonald M, Virani S, Chan M, et al. CCS/CHFS heart failure guidelines update: Defining a new pharmacologic standard of care for HFrEF. *Can J Cardiol.* 2021;37(4):531–546.
18. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF). *Lancet* 2022;400:1938–1952.
19. National Heart Foundation of Australia. Guidelines for the prevention, detection and management of heart failure in Australia 2018. ANZSCTS and Cardiac Society of Australia and New Zealand; 2018. Available at: <https://www.sciencedirect.com/science/article/pii/S1443950618317773>
20. NPS MedicineWise. Heart failure: Taking an active role. September 2021. Available at: <https://www.nps.org.au/professionals/heart-failure-taking-an-active-role>
21. Queensland Government. Heart failure medication optimisation plan. Available at: https://www.health.qld.gov.au/_data/assets/pdf_file/0018/428121/Medn_Titration.pdf
22. Roughead EE, Barratt JD, Ramsay E, et al. Effectiveness of collaborative medicine reviews in delaying time to next hospitalisation for patients with heart failure. *Circ Heart Fail.* 2009;2(5):424–428.
23. Savarese G, Lindberg F, Christodorescu RM, et al. Physician perceptions, attitudes and strategies towards implementing GDMT in HFrEF. *Eur J Heart Fail.* 2024;26(6):1408–1418.
24. Savarese G, Lund LH, Dahlström U, et al. Nurse-led heart failure clinics and outcomes. *J Am Heart Assoc.* 2019;8(10):e011737.
25. Sindone AP, De Pasquale C, Amerena J, et al. Consensus statement on the current pharmacological prevention and management of heart failure. *Med J Aust.* 2022;217(4):212–217.
26. Sindone AP, Haikerwal D, Audehm RG, et al. Clinical characteristics of people with heart failure in Australian general practice. *ESC Heart Fail.* 2021;8(6):4497–4505.
27. Stewart S, Riegel B, Boyd C, et al. ARISE-HF: A multidisciplinary framework to optimise outcomes in heart failure and multimorbidity. *Int J Cardiol.* 2016;212:1–10.
28. Straw S, McGinlay M, Witte KK. Four pillars of heart failure: Contemporary pharmacological therapy for HFrEF. *Open Heart.* 2021;8(1):e001585.
29. Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. Systematic review and network meta-analysis of pharmacological treatment of HFrEF. *JACC Heart Fail.* 2022;10(2):73–84.